Faster targeted therapy and reduction in empiric antifungal costs
The T2Candida® Panel is the first and only FDA-cleared and CE-marked direct-from-blood fungal pathogen detection assay, providing same-day results directly from a whole blood specimen for the most clinically relevant fungi.
T2Candida’s greatest clinical utility is for patients in any of these conditions1:
Admitted to the ICU
Have febrile neutropenia
Have septic shock
Have an LVAD and evidence of active infection
In ICU at high risk for candidemia
Reduction in mortality rates
Candida infections have an overall mortality rate of 40%, but if patients receive targeted treatment within 12 hours, the mortality rate can be reduced to 11%.2,3 T2Candida provides a clear and compelling solution, with results in just hours without waiting for slow-growing fungal infections, which are often mistaken as bacterial infections, to reach positivity.
Unprecedented speed and accuracy
The T2Candida Panel pivotal clinical trial demonstrated results in 3 to 5 hours.4 All other FDA-cleared Candida diagnostic methods require a positive blood culture. Blood culture misses up to half of the infections and often will take 2 to 8 days to become positive.5 Only then can identification be performed. In most cases, a negative result is not confirmed for 5 days after collection and processing of the blood culture.
Faster targeted therapy
Faster time to appropriate therapy has been consistently demonstrated to reduce the overall length of stay in the hospital and ICU and results in a savings of $30,000 per patient.6 See how Henry Ford in Michigan and Lee Health in Florida have demonstrated faster-targeted therapy for patients in clinical care for more than 24 hours.7,8
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Resistance™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
Check out our latest #whitepaper containing clinical trial data, real-world evidence, and example algorithms that detail how T2Candida can be incorporated into practice and improve care for invasive candidiasis in your own practice.